Lidocaína Grindeks (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, keeping them in an inactive state. This prevents the rapid influx of sodium ions needed for depolarisation, thereby halting the generation and spread of action potentials and producing reversible loss of sensation.

The appropriate dose is determined by the prescribing clinician based on the intended procedure, patient weight, age, and clinical condition. Lidocaine dosing must be individualized and follows established medical guidelines.

Safety data for lidocaine during pregnancy and lactation are limited. Use is generally reserved for situations where the benefit to the mother outweighs potential risks to the fetus or infant, and it should be administered under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and necessary import documentation.

Compared with bupivacaine, another amide‑type anesthetic, lidocaine has a faster onset but a shorter duration of action. Bupivacaine provides longer postoperative analgesia but carries a higher risk of cardiotoxicity at equivalent plasma concentrations. Choice depends on the required duration and safety profile for the specific procedure.

Lidocaína Grindeks should be stored below 25 °C, in its original packaging, protected from moisture and direct light. The container must remain sealed until use, and any opened vial should be used within the time frame recommended by the manufacturer to maintain sterility.

The solution is administered by a qualified healthcare professional via epidural, intravenous or subcutaneous injection, depending on the clinical indication. Proper aseptic technique, correct needle placement and dose calculation are essential to achieve effective anesthesia while minimizing toxicity.

Serious adverse events include cardiovascular collapse, severe arrhythmias, central nervous system seizures, and anaphylactic reactions. Early recognition of signs such as profound hypotension, irregular heart rhythm, convulsions or rash is critical, and immediate medical intervention should be initiated.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe heart block, uncontrolled epilepsy, or significant hepatic impairment should avoid using this product unless a risk‑benefit assessment justifies its use.